[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported sales of common stock under a Rule 10b5-1 trading plan adopted August 21, 2024. On 09/03/2025 he sold 2,535 shares at a weighted-average price of $37.82 (individual trade prices ranged $37.39–$38.37) and sold 190 shares at a weighted-average price of $38.55 (trade range $38.54–$38.55). Following those reported transactions the filing shows beneficial ownership totals of 233,738 and 233,548 shares on the separate reporting lines. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Il Chief Medical Officer di Apogee Therapeutics, Carl Dambkowski, ha dichiarato la vendita di azioni ordinarie nell'ambito di un piano di negoziazione ai sensi della Rule 10b5-1 adottato il 21 agosto 2024. Il 03/09/2025 ha venduto 2.535 azioni a un prezzo medio ponderato di 37,82$ (prezzi dei singoli trade compresi tra 37,39$ e 38,37$) e 190 azioni a un prezzo medio ponderato di 38,55$ (range 38,54$–38,55$). Dopo le transazioni riportate, il deposito indica una detenzione effettiva di 233.738 e 233.548 azioni sulle rispettive righe di segnalazione. Il Modulo 4 è stato firmato da un procuratore il 05/09/2025.
Carl Dambkowski, Chief Medical Officer de Apogee Therapeutics, informó ventas de acciones ordinarias bajo un plan de negociación Rule 10b5-1 adoptado el 21 de agosto de 2024. El 03/09/2025 vendió 2.535 acciones a un precio medio ponderado de 37,82$ (precios individuales entre 37,39$ y 38,37$) y 190 acciones a un precio medio ponderado de 38,55$ (rango 38,54$–38,55$). Tras las operaciones reportadas, la presentación muestra una propiedad beneficiaria de 233.738 y 233.548 acciones en las líneas de reporte separadas. El Formulario 4 fue firmado por un apoderado el 05/09/2025.
Apogee Therapeutics의 최고의학책임자(CMO) 칼 댐브코스키는 2024년 8월 21일 채택된 Rule 10b5-1 거래 계획에 따라 보통주 매각을 보고했습니다. 2025년 9월 3일에 그는 가중평균가격 37.82달러로 2,535주를 매도(개별 거래 가격 구간 37.39–38.37달러)하고, 가중평균가격 38.55달러로 190주를 매도(거래 범위 38.54–38.55달러)했습니다. 보고된 거래 이후 제출서류에는 별도 보고 줄에 각각 233,738주와 233,548주의 실질 보유가 표시되어 있습니다. Form 4는 2025년 9월 5일 대리인에 의해 서명되었습니다.
Le Chief Medical Officer d'Apogee Therapeutics, Carl Dambkowski, a déclaré la vente d'actions ordinaires dans le cadre d'un plan de trading Rule 10b5-1 adopté le 21 août 2024. Le 03/09/2025, il a vendu 2 535 actions au prix moyen pondéré de 37,82$ (prix des transactions individuelles entre 37,39$ et 38,37$) et 190 actions au prix moyen pondéré de 38,55$ (plage 38,54$–38,55$). À la suite de ces transactions déclarées, le dépôt indique une détention bénéficiaire de 233 738 et 233 548 actions sur les lignes de déclaration distinctes. Le Formulaire 4 a été signé par un mandataire le 05/09/2025.
Der Chief Medical Officer von Apogee Therapeutics, Carl Dambkowski, meldete den Verkauf von Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans, der am 21. August 2024 angenommen wurde. Am 03.09.2025 verkaufte er 2.535 Aktien zu einem gewichteten Durchschnittspreis von 37,82$ (Einzelhandelspreise zwischen 37,39$ und 38,37$) und 190 Aktien zu einem gewichteten Durchschnittspreis von 38,55$ (Handelsspanne 38,54$–38,55$). Nach den gemeldeten Transaktionen zeigt die Einreichung einen wirtschaftlichen Besitz von 233.738 bzw. 233.548 Aktien in den separaten Meldezeilen. Das Formular 4 wurde am 05.09.2025 von einem Bevollmächtigten unterzeichnet.
- Transactions executed under a Rule 10b5-1 plan, which provides an affirmative defense and indicates preplanned trading
- Detailed price disclosure including weighted-average prices and explicit trade price ranges, with an offer to provide per-price execution breakdowns on request
- Form includes reporting person role (Chief Medical Officer) and post-transaction beneficial ownership figures
- Insider disposed of 2,725 shares (2,535 and 190 shares) which represents a reduction in the reporting person’s holdings
- Weighted-average sale prices reported ($37.82 and $38.55) may warrant reconciliation with market activity for context (not provided in this filing)
Insights
TL;DR: Insider sales were executed under an established 10b5-1 plan, indicating prearranged disposition rather than opportunistic trading.
The filing documents routine disposition activity by a named executive using a Rule 10b5-1 plan adopted August 21, 2024. The plan provides an affirmative defense against insider trading claims because transactions were pre-specified; the filing discloses weighted-average prices and trade price ranges and commits to provide detailed execution breakdowns on request. For compliance reviewers, the key elements are the plan adoption date, clear notation of the 10b5-1 plan checkbox, and the reporting of price ranges and beneficial ownership after the trades.
TL;DR: Sales reduced the reporting person’s holdings by 2,725 shares; disclosure appears complete and includes required price-range detail.
From a governance perspective the filing contains the customary disclosures: relationship to issuer (Chief Medical Officer), transaction dates, codes, amounts sold, weighted-average prices and ranges, and an attorney-in-fact signature. The dual reporting lines showing post-transaction beneficial ownership should be reconciled by investors with prior filings for a full ownership change history, but the Form 4 itself provides the essential elements for transparency.
Il Chief Medical Officer di Apogee Therapeutics, Carl Dambkowski, ha dichiarato la vendita di azioni ordinarie nell'ambito di un piano di negoziazione ai sensi della Rule 10b5-1 adottato il 21 agosto 2024. Il 03/09/2025 ha venduto 2.535 azioni a un prezzo medio ponderato di 37,82$ (prezzi dei singoli trade compresi tra 37,39$ e 38,37$) e 190 azioni a un prezzo medio ponderato di 38,55$ (range 38,54$–38,55$). Dopo le transazioni riportate, il deposito indica una detenzione effettiva di 233.738 e 233.548 azioni sulle rispettive righe di segnalazione. Il Modulo 4 è stato firmato da un procuratore il 05/09/2025.
Carl Dambkowski, Chief Medical Officer de Apogee Therapeutics, informó ventas de acciones ordinarias bajo un plan de negociación Rule 10b5-1 adoptado el 21 de agosto de 2024. El 03/09/2025 vendió 2.535 acciones a un precio medio ponderado de 37,82$ (precios individuales entre 37,39$ y 38,37$) y 190 acciones a un precio medio ponderado de 38,55$ (rango 38,54$–38,55$). Tras las operaciones reportadas, la presentación muestra una propiedad beneficiaria de 233.738 y 233.548 acciones en las líneas de reporte separadas. El Formulario 4 fue firmado por un apoderado el 05/09/2025.
Apogee Therapeutics의 최고의학책임자(CMO) 칼 댐브코스키는 2024년 8월 21일 채택된 Rule 10b5-1 거래 계획에 따라 보통주 매각을 보고했습니다. 2025년 9월 3일에 그는 가중평균가격 37.82달러로 2,535주를 매도(개별 거래 가격 구간 37.39–38.37달러)하고, 가중평균가격 38.55달러로 190주를 매도(거래 범위 38.54–38.55달러)했습니다. 보고된 거래 이후 제출서류에는 별도 보고 줄에 각각 233,738주와 233,548주의 실질 보유가 표시되어 있습니다. Form 4는 2025년 9월 5일 대리인에 의해 서명되었습니다.
Le Chief Medical Officer d'Apogee Therapeutics, Carl Dambkowski, a déclaré la vente d'actions ordinaires dans le cadre d'un plan de trading Rule 10b5-1 adopté le 21 août 2024. Le 03/09/2025, il a vendu 2 535 actions au prix moyen pondéré de 37,82$ (prix des transactions individuelles entre 37,39$ et 38,37$) et 190 actions au prix moyen pondéré de 38,55$ (plage 38,54$–38,55$). À la suite de ces transactions déclarées, le dépôt indique une détention bénéficiaire de 233 738 et 233 548 actions sur les lignes de déclaration distinctes. Le Formulaire 4 a été signé par un mandataire le 05/09/2025.
Der Chief Medical Officer von Apogee Therapeutics, Carl Dambkowski, meldete den Verkauf von Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans, der am 21. August 2024 angenommen wurde. Am 03.09.2025 verkaufte er 2.535 Aktien zu einem gewichteten Durchschnittspreis von 37,82$ (Einzelhandelspreise zwischen 37,39$ und 38,37$) und 190 Aktien zu einem gewichteten Durchschnittspreis von 38,55$ (Handelsspanne 38,54$–38,55$). Nach den gemeldeten Transaktionen zeigt die Einreichung einen wirtschaftlichen Besitz von 233.738 bzw. 233.548 Aktien in den separaten Meldezeilen. Das Formular 4 wurde am 05.09.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did APGE insider Carl Dambkowski sell and when?
Was the sale covered by a 10b5-1 trading plan?
How many shares does the filing show after the transactions?
What prices were the shares sold at?
Who signed the Form 4?
